Ads
related to: brown discharge while on depo
Search results
Results From The WOW.Com Content Network
DMPA, under brand names such as Depo-Provera and Depo-SubQ Provera 104, is used in hormonal birth control as a long-lasting progestogen-only injectable contraceptive to prevent pregnancy in women. [ 38 ] [ 39 ] It is given by intramuscular or subcutaneous injection and forms a long-lasting depot , from which it is slowly released over a period ...
Depot MPA (DMPA) and EC/MPA were developed by Upjohn in the 1960s. [12] [13] DMPA (brand name Depo-Provera) was introduced for use as a progestogen-only injectable contraceptive for the first time outside of the United States in 1969 and was subsequently approved for use in birth control in the United States in 1992.
No. 4: How much discharge your body produces can vary The amount of vaginal discharge a woman’s body makes varies from person to person. Some naturally produce a lot of discharge, while others ...
Micrograph showing navicular cell in extremely high magnification. Navicular cell is a boat-shaped benign epithelial cell seen in Pap smear. [1] They are seen in pregnancy (most prominently during smears taken in the second trimester), [2] second half of menstrual cycle, during menopause and in women using medroxyprogesterone acetate (depo-provera) for contraception.
Estradiol cypionate (EC), sold under the brand name Depo-Estradiol among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for trans women, and in hormonal birth control for women. [14] [8] [15] [16] It is given by injection into muscle once every 1 to ...
Discharge may be red and heavy for the first few days as it consists of blood and the superficial mucous membrane that lined the uterus during pregnancy. This discharge normally begins to taper and should become more watery and change in color from pinkish brown to yellowish white. [14]
Initial evaluation during diagnosis aims at determining pregnancy status, menopausal status, and the source of bleeding. One definition for diagnosing the condition is bleeding lasting more than 7 days or the loss of more than 80 mL of blood heavy flow. [3] Treatment depends on the cause, severity, and interference with quality of life. [4]
[1] [75] [76] [77] As a result, they increase the risk of VTE, especially during pregnancy when estrogen and progesterone levels are very high as well as during the postpartum period. [ 75 ] [ 76 ] [ 78 ] Physiological levels of estrogen and/or progesterone may also influence risk of VTE—with late menopause (≥55 years) being associated with ...